◆英語タイトル:Mylan Laboratories Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013443
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Mylan Laboratories Ltd (Mylan), a subsidiary of Mylan NV is a pharmaceutical company that manufactures and supplies API products. The company offers HIV care products for the treatment of HIV/AIDS. It provides women’s care products for therapies such as hormone replacement therapy, infertility and maintenance of early pregnancy. Mylan offers infertility care products which include follicle stimulating hormone, human menopausal gonadotropins and human chorionic gonadotropins. The company’s onco care division provides cancer-related cytotoxic and targeted therapy products. Its critical care division offers anti-fungal, antibiotic and anticoagulant therapies. The company operates through its manufacturing units in India and China. Mylan is headquartered in Hyderabad, Telangana, India.
Mylan Laboratories Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 10
Partnerships 11
Matrix Labs Plans Co-Marketing Agreement For 100 Products 11
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 12
Licensing Agreements 13
Gilead Sciences Expands Licensing Agreement with Mylan Labs 13
Gilead Sciences Expands Licensing Agreement with Mylan Labs 14
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 15
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 16
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 17
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 19
Mylan Laboratories Ltd – Key Competitors 21
Mylan Laboratories Ltd – Key Employees 22
Mylan Laboratories Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Joint Venture 23
Recent Developments 24
Legal and Regulatory 24
May 29, 2017: Phosphagenic – Mylan Arbitration Update – expert report on quantum of damages claimed filed 24
Jan 06, 2016: Phosphagenics Initiates Arbitration against Mylan 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Tables
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Mylan Laboratories Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 10
Matrix Labs Plans Co-Marketing Agreement For 100 Products 11
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 12
Gilead Sciences Expands Licensing Agreement with Mylan Labs 13
Gilead Sciences Expands Licensing Agreement with Mylan Labs 14
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 15
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 16
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 17
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 19
Mylan Laboratories Ltd, Key Competitors 21
Mylan Laboratories Ltd, Key Employees 22
Mylan Laboratories Ltd, Subsidiaries 23
Mylan Laboratories Ltd, Joint Venture 23